Enhanced Treatment of Gastrointestinal Tract Diseases with JAK Inhibitors and Advanced Delivery Systems

The present inventive concept provides improved methods and compositions for treating diseases of the gastrointestinal tract using JAK inhibitors, featuring advanced delivery systems that enhance efficacy, safety, and patient compliance.

The original patent disclosed methods and compositions for treating gastrointestinal tract diseases with JAK inhibitors, but faced limitations in terms of targeted delivery, optimal dosing, and disease marker detection. The new inventive concept addresses these limitations by introducing advanced delivery systems, including ingestible devices, bioadhesive materials, pH-dependent coatings, and temperature-responsive capsules, which enable more precise and effective treatment.

The inventive concept comprises a system for treating gastrointestinal tract diseases, featuring an ingestible device that releases a pharmaceutical formulation comprising a JAK inhibitor at a predetermined site of disease, equipped with a sensor to detect disease markers and adjust the release of the formulation accordingly. Alternatively, the inventive concept includes a method for treating gastrointestinal tract diseases, comprising orally administering to a subject a pharmaceutical composition comprising a therapeutically effective amount of a JAK inhibitor and a bioadhesive material that enhances retention of the composition at the site of disease. The inventive concept also encompasses a pharmaceutical formulation for treating gastrointestinal tract diseases, comprising a JAK inhibitor and a pH-dependent coating that releases the inhibitor at a predetermined pH range in the gastrointestinal tract. Additionally, the inventive concept includes a device for treating gastrointestinal tract diseases, comprising an ingestible capsule that releases a pharmaceutical formulation comprising a JAK inhibitor in response to a specific temperature range in the gastrointestinal tract. Furthermore, the inventive concept provides a method for monitoring the efficacy of a JAK inhibitor in treating gastrointestinal tract diseases, comprising detecting the concentration of the inhibitor in the plasma of a subject and adjusting the dosage of the inhibitor based on the detected concentration.

The new inventive concept introduces novel and non-obvious advancements over the original patent, including the use of ingestible devices, bioadhesive materials, pH-dependent coatings, and temperature-responsive capsules, which provide targeted and controlled release of JAK inhibitors, thereby enhancing efficacy and reducing side effects. The inventive concept also provides a method for monitoring the efficacy of JAK inhibitors, which enables personalized treatment and optimal dosing.

Alternative embodiments of the inventive concept may include the use of different types of sensors, such as optical or acoustic sensors, to detect disease markers. Additionally, the inventive concept may be adapted for use in treating other diseases or conditions, such as inflammatory bowel disease or cancer, by modifying the pharmaceutical formulation or delivery system.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of gastrointestinal tract diseases, such as Crohn's disease and ulcerative colitis. The advanced delivery systems and personalized treatment approach offered by the inventive concept may improve patient outcomes, reduce healthcare costs, and increase market share for pharmaceutical companies.